-
Markten
-
Aandelen
Sustainable finance2025 Euronext ESG Trends ReportLees meerA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLees meerThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeLees meerInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fondsen
-
Obligaties
European Defence BondsGroupe BPCE lists the first bondLees meerFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Gestructureerde producten
-
Derivaten
Where European Government Bonds Meet the FutureFixed Income derivativesLees meerTrade mini bond futures on main European government bonds
-
Commodities
- Overzicht
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Levering en afwikkeling
- Specificaties en regelingen
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLees meerEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Meer
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLees meerJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Crossject
Identification
Instrument name
CROSSJECT
Symbol
ALCJ
ISIN code
FR0011716265
Exchange / Market
Euronext Growth
Trading location
Paris
Products family
Stocks
ICB
Medical Supplies
Activity description
Crossject est spécialisé dans la fabrication et la commercialisation de systèmes d’auto-injection médicamenteuse sans aiguille. Le groupe propose Zeneo, un dispositif pré-rempli et à usage unique, pouvant être utilisé pour des injections intradermiques, sous cutanées et intramusculaires. Le CA par activité se répartit comme suit :
- prestations de collaboration sur le méthotrexate (70,6%) ;
- prestations de collaboration sur le traitement des oedèmes maculaires (28,3%) ;
- autres (1,1%).
La totalité du CA est réalisée en France.
Website address
http://www.crossject.com/
Operation
IPO date
do 20/02/2014
IPO type
Introduction par offre au public
IPO price
8,38 EUR
IPO type
Initial Public offering
Catégorie
IPO
Price range
EUR 7.21 - EUR 8.38
Capital raised
17